Saptalis Pharmaceuticals

5 articles about Saptalis Pharmaceuticals

• 

  Appili Gets FDA Approval for Liquid, Oral Reformulation of Antibiotic Metroni...

  9/26/2023

  The FDA on Monday approved the Canadian biopharma’s liquid antibiotic metronidazole, an alternative for patients who are unable to use pills or injections.

• Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral Suspension

  9/25/2023

  Appili Therapeutics Inc. today announced that its manufacturing and commercialization partner, Saptalis Pharmaceuticals, LLC (“Saptalis”) received approval from the U.S. Food and Drug Administration ("FDA”) for Metronidazole Oral Suspension 500mg/5mL (ATI-1501).

• Appili Therapeutics Expands ATI-1501 Commercial Agreement with Partner Saptalis Pharmaceuticals

  2/8/2022

  Appili Therapeutics Inc. announced today it has amended its agreement with Saptalis Pharmaceuticals LLC o expand the territories in which Saptalis will commercialize ATI-1501, Appili’s liquid oral reformulation of the antibiotic metronidazole.

• Micro Labs USA Inc and Saptalis Pharmaceuticals LLC Announce Launch of Metformin Oral Solution (500 mg/5mL in two presentations 118mL and 473mL)

  5/13/2020

   Micro Labs USA , Inc. and Saptalis Pharmaceuticals, LLC. are strengthening their association with the launch of Metformin Oral Solution in the US market. Metformin Oral Solutio

• New York's Saptalis Expands Production into New 28,000 Sq. Ft. Plant

  8/8/2017